The c-fms proto-oncogene encodes a transmembrane glycoprotein that is closely related or identical to the receptor for the monocyte colony-stimulating factor CSF-1. The present studies examined the mechanisms responsible for the regulation of c-fms gene expression during human monocytic differentiation. Levels of c-fms mRNA were undetectable in HL-60 promyelocytic leukemia cells, while 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced monocytic differentiation of these cells was associated with the appearance of these transcripts. Run-on transcription assays demonstrated that the c-fms gene was transcriptionally active in uninduced HL-60 cells and that the rate of transcription was unchanged after TPA treatment. These findings suggested that c-fms mRNA levels in HL-60 cells are controlled by posttranscriptional mechanisms. The half-life of c-fms transcripts in TPA-induced HL-60 cells was found to be at least 6 h, while inhibition of protein synthesis with cycloheximide (CHX) decreased this half-life to 4 h. Moreover, inhibition of protein synthesis was associated with decreases in c-fms mRNA levels and a block in the induction of c-fms transcripts by TPA. These findings indicated that the c-fms transcript is stabilized by a labile protein. In contrast to HL-60 cells, c-fms mRNA is constitutively expressed in resting human monocytes and is down-regulated by treatment of these cells with TPA. Run-on assays demonstrated that TPA-induced downregulation of c-fms mRNA levels in monocytes occurred at the posttranscriptional level. Moreover, the results demonstrate that levels of c-fms mRNA are regulated posttranscriptionally by a labile protein. In this regard, the half-life of the c-fms transcript was 6.1 h in monocytes, while treatment of these cells with CHX decreased the half-life to 30 min. Furthermore, this effect of CHX occurred in the absence of changes in the rate of c-fms gene transcription. Together, these findings indicate that c-fms gene expression is regulated at a posttranscriptional level both in HL-60 cells induced to differentiate along the monocytic lineage and in human monocytes. The findings also indicate that levels of c-fms mRNA are regulated by the synthesis of a labile protein which is involved in stabilization of the c-fms transcript.
The colony-stimulating factor CSF-1 is required for the survival and proliferation of monocytes, macrophages, and progenitors of the mononuclear phagocyte lineage (26) . Moreover, CSF-1 induces the differentiation of monocytes to macrophages and stimulates their production of cytokines, such as interferon, tumor necrosis factor, and granulocyte colony-stimulating factor (1, 26, 30) . These effects of CSF-1 are mediated by its interaction with a single class of high-affinity cell surface receptors (26) . The identification of CSF-1 receptors on cells of trophoblastic origin has suggested that CSF-1 may also play a role in placental development (17, 19, 31) .
The CSF-1 receptor is closely related or identical to the product of the c-fms proto-oncogene (25) . The c-fms gene is the normal cellular homolog of the v-fms oncogene from the McDonough strain of the feline sarcoma virus (6) . c-fms transcripts are detectable in placental tissue (13) , choriocarcinoma cells (14) and cells differentiated along the monocyte lineage (15, 23) . Furthermore, the c-fms gene product is expressed on monocytes and choriocarcinoma cell lines (19, 31) , exhibits tyrosine kinase activity (19, 31) , and specifically binds CSF-1 (19) . These and other findings have demonstrated that the c-fms gene is related to a family of genes coding for growth factor receptors with intrinsic tyrosine kinase activity.
Recent studies have demonstrated that CSF-1 is produced by monocytes (7-9, 16, 18) . Furthermore, CSF-1 gene expression is often detectable in cells differentiated along the monocytic lineage which also express the c-fms gene (29) . These findings have suggested that monocytes regulate their own growth and differentiation through the autocrine production of CSF-1. However, the mechanisms responsible for the regulation of CSF-1 and c-fms gene expression during monocytic differentiation have not been defined. We have recently shown that CSF-1 gene transcription is at low or undetectable levels in resting monocytes and that this gene is activated following treatment of these cells with phorbol esters (7) . Moreover, CSF-1 mRNA levels in monocytes are regulated at the posttranscriptional level by labile proteins (7) . While this control of CSF-1 gene expression would contribute to the autocrine regulation of monocytes, mechanisms responsible for regulating c-fms gene expression may also play a role.
The present studies have examined the regulation of c-fms gene expression during monocytic differentiation. Previous studies have demonstrated that the c-fms gene is expressed when human HL-60 myeloid leukemic cells are induced to differentiate along the monocytic lineage with phorbol esters (23) . Furthermore, the c-fms gene is constitutively expressed in human peripheral blood monocytes (15, 23) , and the level of c-fms transcripts is down-regulated following activation of these cells (9) . The were grown in RPMI 1640 medium supplemented with 15% heat-inactivated fetal bovine serum (Hazelton) in 5% CO2 at 37°C. 12-0-Tetradecanoylphorbol-13-acetate (TPA) (Sigma Chemical Co.) was dissolved in 1% acetone at 3.2 ,uM and used at a final concentration of 16 or 32 nM. Peripheral blood monocytes were obtained as by-products of plateletpheresis from normal blood donors by a previously described method (21) . Cell viability was determined by trypan blue exclusion.
RNA extraction and hybridization. HL-60 cells and monocytes were harvested at various intervals after drug treatment. Total cellular RNA was purified by the guanidine isothiocyanate-cesium chloride method, analyzed by gel electrophoresis, transferred to nitrocellulose paper, and hybridized to appropriate DNA probes by previously described methods (23) . The 4.0-kilobase (kb) EcoRI fragment of the human c-fms gene in the pc-fmslO2 plasmid (5) and the 2.0-kb PstI fragment of the chicken 3-actin gene in the pAl plasmid (4) were labeled by primer extension with [aL-32P] dCTP (3,000 Ci/mmol; Amersham Corp.) to yield specific activities of approximately 108 cpm/,ug. Filters were then washed, dried, and exposed to Kodak XAR-5 film for 1 to 7 days. Relative signal intensity was determined by laser densitometry. The mRNA half-life was calculated by the method of least squares.
Nuclear run-on assays. Cells were treated as indicated, pelleted at 500 x g, and washed twice with ice-cold phosphate-buffered saline. The cells were then suspended in 4 ml of ice-cold lysis buffer (10 mM Tris hydrochloride [pH 7.4], 10 mM NaCl, 3 mM MgCl2, 0.5% Nonidet P-40), vortexed gently for 20 s, and left on ice for 5 min. Nuclei were then pelleted for 5 min at 500 x g. The supernatant was removed, and the above procedure was repeated. Nuclei were suspended in 100 ,u1 of 65°C in 10 mM TES [N-tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid, pH 7.5]-300 mM NaCl-10 mM EDTA-0.2% SDS-0.5 p.g of tRNA per ml-0.5 p.g of salmon sperm DNA per ml-0.05% sodium pyrophosphate-2x Denhardt solution (1 x Denhardt solution is 0.02% bovine serum albumin, 0.02% Ficoll, and 0.02% polyvinylpyrrolidone). Hybridizations were performed with equal amounts of labeled nuclear RNA in 10 mM TES (pH 7.5)-300 mM NaCI-10 mM EDTA-0.2% SDS for 48 h at 65°C. The filters were then washed twice at 37°C in, successively, 2x SSC-0.1% SDS, 2x SSC, 2x SSC-10 p.g of RNase per ml, and O.lx SSC-0.1% SDS before autoradiography. RESULTS HL-60 promyelocytic leukemia cells. HL-60 cells are induced to differentiate along the monocytic lineage following exposure to phorbol esters, such as TPA (23) . c-fms gene expression is one event associated with this induction of the monocytic phenotype (23) . In the present work, TPA treatment was similarly associated with the appearance of c-fms transcripts by 3 h (Fig. 1A) . c-fms mRNA reached maximal levels by 24 h, which were undiminished at 48 h (Fig. 1A ). This increase in the level of c-fms mRNA was associated with the appearance of monocyte-specific cell surface antigens and histochemical staining patterns characteristic of the monocytic lineage (23) (data not shown).
Run-on transcription assays were performed to determine relative rates of c-fms gene transcription in nuclei isolated from uninduced and TPA-treated HL-60 cells. Despite the absence of detectable c-fms RNA, the c-fms gene was transcriptionally active in untreated HL-60 cells (Fig. 1B) . Furthermore, although associated with the accumulation of c-fms transcripts, there was no detectable increase in the transcription rate of the c-fms gene following exposure to TPA for 24 h (Fig. 1B) . The hybridization of labeled nuclear RNA to pBR322 DNA without an insert served as the negative control (Fig. 1B) 5 ,ug/ml) was then added for the indicated times. Total cellular RNA was analyzed as described in the legend to transcriptional activity occurred in the presence of increases in the rate of CSF-1 gene transcription (data not shown). These results suggested that the increase in c-fms mRNA levels following TPA exposure occurred as a result of posttranscriptional mechanisms.
Subsequent studies were performed to determine the stability of the c-fms transcript. HL-60 cells were treated with TPA for 18 h and then treated with dactinomycin for various intervals. The levels of c-fms mRNA progressively decreased during 2 to 12 h of dactinomycin exposure ( Fig.  2A) . Dactinomycin similarly decreased actin mRNA levels, although there was little effect on these transcripts through the initial 6 h of treatment ( Fig. 2A) . While there was no detectable loss of cell viability under these experimental conditions, declines in mRNA levels following longer (over 6 h) dactinomycin exposures could be related to the cytotoxic effects of this agent. Although the calculated half-life of the c-fms transcript was 6.0 h (Fig. 2B) , these findings suggested that the half-life of c-fms mRNA is at least 6 h and possibly longer.
In order to determine whether the stability of the c-fms transcript was affected by inhibition of protein synthesis, TPA-treated HL-60 cells were exposed to cycloheximide (CHX) for 3 h before dactinomycin was added. In these experiments, dactinomycin exposure was limited to 5 h and was associated with a progressive decline in c-fms mRNA levels (Fig. 3A) . In contrast, there was little if any effect on the levels of actin mRNA (Fig. 3A) . The half-life for the c-fms transcripts in these CHX-treated HL-60 cells was 4.0 h (Fig. 3B) . These results, when taken together with the findings for HL-60 cells treated with dactinomycin alone (Fig. 2) , suggested that inhibition of protein synthesis is associated with destabilization of c-fms mRNA.
Further studies were performed with CHX to confirm the effects of this agent on c-fis mRNA levels. HL-60 cells were treated with TPA for 18 h and then exposed to both TPA and CHX (in the absence of dactinomycin) for 3 h. As shown in Fig. 4A , CHX decreased the level of c-fms mRNA by 65% compared with that in cells treated with only TPA. Furthermore, treatment with CHX under these conditions had no detectable effect on actin mRNA levels (Fig. 4A) . These findings supported the involvement of a labile protein in the stabilization of c-fms transcripts and suggested that CHX might also inhibit the increases in c-fms mRNA levels A. B. induced by TPA. In order to determine whether the increase in c-fms mRNA levels similarly required the synthesis of a labile protein, cells were treated with increasing concentrations of CHX for 1 h before TPA was added. While CHX at 0.1 ,ug/ml had no detectable effect, higher CHX concentrations progressively inhibited the appearance of c-fms mRNA (Fig. 4B) . In contrast, CHX had little effect on actin mRNA levels (Fig. 4B) . Together, these findings supported the involvement of a labile protein in the stabilization of c-fms transcripts and in the regulation of c-fms expression during treatment with TPA.
Run-on assays were also performed to determine whether exposure to CHX and TPA affects the transcriptional rate of the c-fms gene. As shown in Fig. 5 , treatment of HL-60 cells with TPA for 18 h and then with both TPA and CHX for an additional 3 h had no detectable effect on the rate of c-fms gene transcription compared with that in control cells. Treatment of cells with CHX for 1 h before the addition of TPA for an additional 24 h also had no detectable effect on the rate of c-fms gene transcription (Fig. 5) . These findings thus confirmed that the effects of CHX were at the posttranscriptional level and that the c-fms transcript is stabilized by a labile protein in TPA-treated cells.
Peripheral blood monocytes. The regulation of c-fms gene expression was also studied in human peripheral blood monocytes. Previous studies have demonstrated expression of the c-fms gene in preparations of resting monocytes (9, 23) . In contrast, treatment of monocytes with TPA was associated with decreases in the level of c-fms mRNA (Fig.  6A) . This downregulation of c-fms expression was detectable after 3 h of TPA exposure, and the c-fms mRNA reached almost undetectable levels by 24 h (Fig. 6A) . In contrast, TPA had no detectable effect on the level of actin mRNA (data not shown). Run-on assays were performed to determine whether decreases in transcription of the c-fms gene were responsible for the decline in the level of these transcripts. c-fms gene transcription was detectable in resting monocytes (Fig. 6B) . Furthermore, treatment with TPA for 24 h had no detectable effect on the rate of c-fms gene transcription despite the marked decrease in c-fms mRNA levels (Fig. 6B) . In contrast, TPA treatment was associated with increases in CSF-1 gene transcription (7) (data not shown). These findings thus suggested that the effects of TPA on c-fms transcripts in monocytes occurred at the posttranscriptional level. Stability of the c-fins transcript was also studied in monocytes to confirm whether regulation was occurring at the posttranscriptional level. Resting monocytes were treated with dactinomycin and monitored for decreases in c-fms mRNA levels. Under these conditions, there was a progressive decline in the level of c-fms transcripts (Fig. 7A) . Furthermore, treatment of these monocytes with both dactinomycin and TPA resulted in even further decreases in the level of c-fms mRNA compared with that in cells treated with dactinomycin alone (Fig. 7A) . Similar findings were obtained when monocytes were treated with dactinomycin A. Effects of dactinomycin (ACT), TPA, and CHX on c-fms mRNA levels in monocytes. (A) Resting monocytes were exposed to dactiriomycin (5 ,ug/ml) for 30 min to 6 h. Monocytes were also exposed to dactinomycin for 6 h and either TPA or CHX for 3 h (h 4 to 6). Total cellular RNA was hybridized to the 32P-labeled c-fms probe. (B) The calculated half-life of the c-fms mRNA in dactinomycin-treated monocytes was 6.1 h (R = 0.96) (see Fig. 2 legend) . assays were also performed with nuclei from monocytes treated with CHX. The rate of c-fms gene transcription was similar in control and CHX-treated cells (Fig. 9) . Together, these results suggested that c-fms gene expression in monocytes is controlled at a posttranscriptional level and that the c-fms transcript is stabilized by a labile protein. and CHX (Fig. 7A) . The half-life of c-fms mRNA in dactinomycin-treated monocytes was 6.1 h (Fig. 7B) . However, the additional decrease in c-fms mRNA levels after exposure of transcriptionally inactive cells to TPA or CHX suggested that these agents resulted in a more rapid degradation of the c-fms transcript (Fig. 7A) .
The finding that CHX decreased c-fms RNA levels in dactinomycin-treated monocytes further suggested that a labile protein was responsible for stabilizing this transcript in monocytes. Indeed, exposure of monocytes to CHX alone for 3 and 6 h resulted in decreased levels of c-fms mRNA (Fig. 8A) . Furthermore, treatment with CHX for 3 h and then with dactinomycin for increasing intervals (Fig. 8A ) resulted in progressive declines in c-fms mRNA levels at a half-life of 30 min for the c-fms transcript (Fig. 8B ). This finding was in contrast to the 6.1-h half-life for c-fms mRNA in monocytes treated in the absence of CHX (Fig. 7) . The finding that CHX and dactinomycin resulted in more pronounced decreases in the levels of these transcripts compared with their levels in monocytes treated with CHX alone suggested that the effects of CHX occurred at the posttranscriptional level. In order to confirm these results, run-on Treatment of human monocytes with TPA induces a more differentiated phenotype, with acquisition of morphologic, biologic, and antigenic characteristics of macrophages (3, 10, 12, 27, 28) . For example, phosphorylation of the CR1 complement receptor following TPA exposure enables monocytes to mediate phagocytosis (3). TPA also induces production of tumor necrosis factor by monocytes (20) and enhances their ability to mediate tumoricidal activity (12) . Moreover, TPA induces CSF-1 gene expression in monocytes (7, 9) . CSF-1 gene transcription is at low or undetectable levels in untreated monocytes, while exposure to TPA is associated with transcriptional activation and induction of CSF-1 transcripts (7). In contrast, the c-fms gene is constitutively expressed in resting monocytes, and the level of c-fms RNA is downregulated during TPA treatment. The present results also demonstrate that this decrease in c-fms expression is regulated at the posttranscriptional level. Thus, CSF-1 and c-fms gene expression appears to be controlled by different mechanisms in monocytes as well as in HL-60 cells.
Posttranscriptional mechanisms responsible for the regulation of gene expression can involve the modification of existing factors or the synthesis of new proteins. In the present studies, the posttranscriptional mechanism responsible for regulating c-fms expression appears to involve the synthesis of a labile protein. In this regard, CHX inhibited the increases in c-fms transcripts associated with TPA treatment of HL-60 cells. Moreover, the finding that the c-fms transcript is stabilized by a labile protein suggests that TPA induces the synthesis of this protein and thereby the increase in c-fms mRNA levels. In addition to the induction of c-fms transcripts in HL-60 cells, TPA also downregulated the constitutive expression of c-fms mRNA in resting monocytes. This downregulation is in concert with previous findings that treatment of monocytes with TPA is associated with activation to cells characteristic of macrophages (3, 10, 12, 27, 28) and c-fms mRNA levels are decreased in macrophages (22) . The present results demonstrate that the downregulation of c-fms expression in TPA-treated monocytes occurs at the posttranscriptional level. This effect may similarly reflect the presence of a labile protein, since CHX also decreased c-fms mRNA levels in monocytes by a VOL. 9, 1989 posttranscriptional mechanism. Thus, while TPA increases c-fms expression in the less differentiated HL-60 cells and downregulates these transcripts in monocytes, the effects of this agent could be related to the synthesis of a labile protein, involved in stabilizing the c-fms transcript, which increases as myeloid cells differentiate to monocytes and then declines with further maturation along this lineage.
Finally, the finding that a labile protein stabilizes the c-fms transcript during monocytic differentiation is in contrast to the posttranscriptional regulation of CSF-1 gene expression. While CSF-1 mRNA levels are also regulated by a labile protein, this protein is associated with degradation of the CSF-1 transcript (7). CSF-1, certain other cytokines, and certain proto-oncogenes contain A+U-rich sequences in the 3' untranslated regions of their mRNAs (2, 24) . These sequences may represent recognition sites for RNases which specifically degrade these transcripts (2, 24) . For example, transient expression of the tumor necrosis factor gene and the c-fos gene is also downregulated at a posttranscriptional level by labile proteins in monocytes (20, 21) . The A + U-rich sequences are present in these mRNAs but not in the c-fms transcript. Thus, the posttranscriptional regulation of c-fms expression is clearly in contrast to that for certain cytokines, such as CSF-1, and other proto-oncogenes.
Moreover, transcript stabilization rather than degradation by proteins has not been widely recognized as a mechanism for the control of gene expression in eucaryotic cells (11) . Consequently, identificaiton of the labile protein involved in stabilization of the c-fms transcript may be helpful in understanding the regulation of gene expression during monocytic differentiation.
